NEW YORK (AP) ¿ Delcath Systems Inc. said Monday the Food and Drug Administration gave its developing liver cancer treatment doxorubicin orphan drug status. Orphan drug status is given to drugs aimed at rare conditions or conditions that have a lack of treatments on the market. Incentives include seven years of market exclusivity following FDA approval, assistance in clinical trial design, a reduction in user fees, and tax credits. Delcath focuses on using drug delivery technology that gives ultra-high doses of anticancer drugs to the liver. Shares of Delcath rose $1.46, or 48 percent, to $4.50 in premarket trading. The stock has ranged from 82 cents to $4.11 over the past year.
More from Food & Drink
Here's How Beyond Meat Will Look After All the Fat's Burned Off
After falling from around $240 to around $140 at the end of July, BYND may have triggered a pattern that will carry it to around $100 and fill the gap of early June.
Shake Shack Sizzles as Price Target Is Raised at SunTrust
Shake Shack has a new 'delicious' BLT sandwich in the works, which is enough for SunTrust to raise its price target on the stock.
Beyond Meat Is Likely to Decline Further in the Days and Weeks Ahead
No reason to buy in bulk.
Performance Food's Fourth-Quarter Results Whet Investors' Appetite
The food distributor beats analysts' estimates. The high end of its expected fiscal 2020 earnings range beats analysts' expectations as well.